REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pi...
Applied Therapeutics is a clinical-stage biopha...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unl...
Selecta Biosciences, Inc. is a clinical-stage b...
Coloplast develops products and services that make life easier for people with ver...
Coloplast develops products and services that m...
Aviana Molecular Technologies, LLC (Aviana) is an Orlando, FL based point of care ...
Aviana Molecular Technologies, LLC (Aviana) is ...
T2 Biosystems, a leader in the development and commercialization of innovative med...
T2 Biosystems, a leader in the development and ...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
Join the National Investor Network and get the latest information with your interests in mind.